scholarly journals Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis

2009 ◽  
Vol 11 (2) ◽  
pp. R39 ◽  
Author(s):  
Yueh-Sheng Chen ◽  
Weixing Yan ◽  
Carolyn L Geczy ◽  
Matthew A Brown ◽  
Ranjeny Thomas
Keyword(s):  
Rheumatoid Arthritis ◽  
Advanced Glycation End Products ◽  
Serum Levels ◽  
Vascular Damage ◽  
S100 Proteins ◽  
Soluble Receptor ◽  
Risk Markers ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

scholarly journals Soluble Receptor for Advanced Glycation End Products and Its Correlation with Vascular Damage in Adolescents with Obesity

2019 ◽  
Vol 92 (1) ◽  
pp. 28-35 ◽  
Author(s):  
Reyna Rodríguez-Mortera ◽  
Claudia Luevano-Contreras ◽  
Sergio Solorio-Meza ◽  
Armando Gómez-Ojeda ◽  
Russell Caccavello ◽  
...  
Keyword(s):  
Advanced Glycation End Products ◽  
Vascular Damage ◽  
Atherogenic Index ◽  
Stiffness Index ◽  
Model Assessment ◽  
Soluble Receptor ◽  
Advanced Glycation ◽  
Cross Sectional ◽  
Glycation End Products ◽  
End Products

Objective: The aim of this study was to evaluate soluble receptor for advanced glycation end products (sRAGE) and advanced glycation end products (AGEs) in adolescents with and without obesity (OB) and their correlation with vascular damage. Methods: This is a cross-sectional study with 15–19 years old adolescents: 33 with OB and 33 with normal weight (NW), each group included 17 male and 16 female. Lipid profile, insulin, carboxymethylysine (CML), sRAGE, total AGEs, and dietary AGEs intake (dAGEs) were evaluated. Vascular damage was measured by flow-mediated vasodilation (FMD) and arterial stiffness index (Iβ). Homeostatic model assessment-insulin (HOMA-IR) and atherogenic index (AI) were calculated. Results: The group with OB had higher triglycerides (TG; p < 0.0001), AI (p < 0.001), HOMA-IR (p < 0.0001), dAGEs intake (p < 0.0001), lower CML (p = 0.05), total AGEs (p < 0.01), sRAGE (p < 0.001), and FMD (p < 0.002). In the total group, sRAGE correlated with AI (r = –0.26 p = 0.037); in the NW group, CML correlated with Iβ (r = –0.36; p = 0.037); and in the group of adolescents with OB, sRAGE correlated with FMD (r = –0.37; p = 0.037) and Iβ (r = 0.47; p = 0.006), while CML and total AGEs correlated with AI, p = 0.007 and p < 0.01, respectively). Conclusions: The group of adolescents with OB showed higher cardiometabolic risk as shown by higher TG, AI, HOMA-IR, and lower sRAGE and FMD. sRAGE correlated negatively with FMD and positively with Iβ, so it could be suggested as a biochemical marker of impaired endothelial function.

Relationship between serum-soluble receptor for advanced glycation end products (sRAGE) and disease activity in rheumatoid arthritis patients

2019 ◽  
Vol 29 (6) ◽  
pp. 943-948 ◽  
Author(s):  
Mohammad Reza Jafari Nakhjavani ◽  
Mahdi Jafarpour ◽  
Amir Ghorbanihaghjo ◽  
Sima Abedi Azar ◽  
Aida Malek Mahdavi
Keyword(s):  
Rheumatoid Arthritis ◽  
Disease Activity ◽  
Advanced Glycation End Products ◽  
Soluble Receptor ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

Serum Levels of Soluble Receptor for Advanced Glycation End Products Are Reduced in Euthyroid Children with Newly Diagnosed Hashimoto’s Thyroiditis: A Pilot Study

2021 ◽  
pp. 1-7
Author(s):  
Tommaso Aversa ◽  
Rosaria Maddalena Ruggeri ◽  
Domenico Corica ◽  
Maria Teresa Cristani ◽  
Giorgia Pepe ◽  
...  
Keyword(s):  
Advanced Glycation End Products ◽  
Hashimoto’S Thyroiditis ◽  
Pediatric Patients ◽  
Serum Levels ◽  
Hashimoto's Thyroiditis ◽  
Soluble Receptor ◽  
Newly Diagnosed ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

<b><i>Objective:</i></b> No data are available on advanced glycation end products (AGEs) and their soluble receptor (sRAGE) in pediatric patients with Hashimoto’s thyroiditis (HT). The present study was aimed to simultaneously evaluate serum levels of sRAGE, AGEs, and advanced oxidation protein products (AOPPs) and investigate the relationships between these oxidative stress markers and clinical and biochemical parameters of thyroid function in euthyroid children with HT. <b><i>Design:</i></b> This is a case-control study carried out in a single university hospital center. <b><i>Methods:</i></b> We enrolled 19 newly diagnosed euthyroid HT pediatric patients (3 M, 16 F; median age 12.44 years, range 6.54–15.81 years) and 16 age-, sex-, and BMI-matched healthy controls (5 M, 11 F; median age 12.83 years, range 5.68–15.07 years). None was on levothyroxine treatment. The exclusion criteria were autoimmune, inflammatory, and infection comorbidities. Patients did not differ significantly from controls with regard to lipid or for anthropometric parameters. <b><i>Results:</i></b> sRAGE levels were significantly lower in HT patients (median 414.30 pg/mL, range 307.30–850.30 pg/mL) than in controls (561.30, 273.20–1121.60 pg/mL; <i>p</i> = 0.034). No differences emerged between patients and controls with regard to serum AGEs (124.25 AU/g prot, 71.98–186.72 vs. 133.90, 94.06–200.78 AU/g prot, <i>p</i> = 0.707) and AOPPs (1.13 nmol/mL, 0.62–1.83 vs. 1.17, 0.76–1.42 nmol/mL, <i>p</i> = 0.545). <b><i>Conclusions:</i></b> sRAGE levels were decreased in euthyroid children/adolescents at the onset of HT, suggesting that autoimmunity per se seems to play an important role in such a reduction of sRAGE, irrespective of any functional alteration. Children and adolescents suffering from HT may exhibit increased susceptibility to oxidative damage, even when in euthyroid status.

scholarly journals Integrative Genomic Analysis Identifies the Soluble Receptor for Advanced Glycation End Products as Putatively Causal for Rheumatoid Arthritis

2020 ◽  
Author(s):  
Gha Young Lee ◽  
Chen Yao ◽  
Shih Jen Hwang ◽  
Roby Joehanes ◽  
Dong Heon Lee ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Cardiovascular Disease ◽  
Advanced Glycation End Products ◽  
Genetic Variants ◽  
Soluble Receptor ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products ◽  
The Uk ◽  
Related Proteins

ABSTRACTObjectivesIdentifying causal biomarkers of rheumatoid arthritis (RA) to improve treatment and monitor disease progression remains a critical but elusive goal. To search for putatively causal protein biomarkers of RA, we designed an integrative genomic strategy utilizing Mendelian randomization (MR), which allows for causal inference between an exposure and an outcome by incorporating genetic variants associated with an exposure (circulating protein level) and inferring its effect on the outcome (rheumatoid arthritis).MethodsWe utilized genetic variants associated with 71 cardiovascular disease-related proteins measured in nearly 7000 Framingham Heart Study participants in conjunction with variants associated with RA in a genome-wide association study (GWAS) from the UK Medical Research Council Integrative Epidemiology Unit (19,234 cases, 61,565 controls) to identify putatively causal proteins for RA. In addition, we applied MR to study circulating rheumatoid factor (RF) levels using GWAS of RF from the UK Biobank (n=30,565) as the outcome.ResultsWe identified the soluble receptor for advanced glycation end products (sRAGE), a critical inflammatory pathway protein, as putatively causal and protective for both RA (odds ratio per 1 standard deviation increment in inverse-rank normalized sRAGE level=0.482; 95% confidence interval 0.374-0.622; p=1.85×10−08) and RF levels (β [change in RF level per sRAGE increment]=-1.280; SE=0.434; p=0.003).ConclusionsBy integrating GWAS of 71 cardiovascular disease-related proteins, RA, and RF, we identified sRAGE as a putatively causal protein protective for both RA ad RF levels. These results highlight the AGER/RAGE axis as a promising new target for RA treatment.

Sign in / Sign up

Export Citation Format

Share Document